WO1990012030A1 - Antigenes de la bacterie de rickettsia pour la vaccination et le diagnostic - Google Patents

Antigenes de la bacterie de rickettsia pour la vaccination et le diagnostic Download PDF

Info

Publication number
WO1990012030A1
WO1990012030A1 PCT/US1990/001678 US9001678W WO9012030A1 WO 1990012030 A1 WO1990012030 A1 WO 1990012030A1 US 9001678 W US9001678 W US 9001678W WO 9012030 A1 WO9012030 A1 WO 9012030A1
Authority
WO
WIPO (PCT)
Prior art keywords
serine
glutamine
glycine
amino acid
alanine
Prior art date
Application number
PCT/US1990/001678
Other languages
English (en)
Inventor
Travis Clinton Mcguire
Guy Hughes Palmer
Anthony Francis Barbet
William Charles Davis
David Redding Allred
Original Assignee
Washington State University Research Foundation, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Washington State University Research Foundation, Inc. filed Critical Washington State University Research Foundation, Inc.
Priority to AU55214/90A priority Critical patent/AU644362B2/en
Priority to CA002049986A priority patent/CA2049986A1/fr
Publication of WO1990012030A1 publication Critical patent/WO1990012030A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/29—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Richettsiales (O)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention primarily relates to antigenic polypeptides and proteins, related vaccines and methods useful to induce an immune response which is protective to reduce the severity or prevent infection by rickettsial parasites of the order Rickettsiales, family Rickettsia, more particularly rickettsiae (or rickettsias) of the genus Anaplasma, even more particularly rickettsias of the species Anaplasma marginale.
  • Rickettsiae are very small parasitic microorganisms (approximately 0.2 micron) which are of the taxonomical order Rickettsiales, family Rickettsia. Rickettsial diseases caused by these parasites have been very significant throughout history to both humans and animals. Hum an deaths caused by outbreaks of epidemic typhus and scrub typhus number in the millions. Epidemic typhus is caused by the rickettsia Rickettsia prowazeki. Scrub typhus is caused by the rickettsia Rickettsia tsutsugamushi which is st ⁇ l endemic in many rural areas of Southeast Asia and Japan. Rocky Mountain spotted fever, caused by Rickettsia rickettsii, is widespread in the eastern United States and is a risk in many other parts of the country.
  • Animal diseases caused by rickettsiae include Rocky Mountain spotted fever and canine ehrlichiosis, caused by Ehrlichia canis, both of which afflict dogs.
  • Rickettsial diseases of horses include equine ehrlichiosis, caused by Ehrlichia equis, and Potomac fever, caused by Ehrlichia risticii. Serious losses occur to cattle from the rickettsia Anaplasma marginale.
  • Some animal rickettsial diseases are communicable to humans, for example, Q-fever, canine ehrlichiosis and Potomac fever. Despite the widespread significance of rickettsial diseases, little has been known about the molecular biology of the rickettsiae.
  • Anaplasmosis is an arthropod borne hemoparasitic disease of cattle and other ruminants caused by Anaplasma marginale. Anaplasmosis occurs worldwide and severely constrains livestock production in tropical and subtropical regions. This rickettsia is transmitted by ticks, biting flies, and blood contaminated fomites to susceptible animals, where it infects red blood cells (erythrocytes). Anaplasma marginale occurs in the red blood cells as an intraerythrocytic initial body, which is a single Anaplasma marginale organism in a mature infective stage of the microbe's life cycle. The infective initial bodies reproduce by binary fission within the erythrocytes to form two to eight initial bodies which are subsequently released to infect additional erythrocytes.
  • This inoculum may also transmit other hemoparasites, such as Babesia, Theileria, and Trypanosoma, and viruses, such as leukemia virus, to the animal being treated.
  • Challenge of cattle immunized with the killed Anaplasma marginale-erythrocyte stroma vaccine results in mild clinical disease and persistent infection.
  • the presence of eiythrocyte stroma in the vaccine has been shown to induce anti-eiythrocyte antibodies which can be transferred through a cow's colostrum to a nursing calf thus causing the autoimmune disease neonatal isoeiythrolysis.
  • Fig. 1A is a reproduction of four radiographs (1)-(4) showing the detection of native Anaplasma marginale proteins on nitrocellulose using four different types of antibody or antiserum.
  • Fig. 1B is a reproduction of a radiograph showing the detection of proteins from recombinant-plasmid-containing E. coli on nitrocellulose.
  • the proteins where screened for reaction with rabbit antiserum R873, which is reactive to the native Anaplasma marginale surface protein complex alternatively referred to as MSP-1 or Am105.
  • Fig. 2 is a restriction enzyme map showing relevant portions of the Anaplasma marginale gene coding for the expression of the protein recombinant Am105. The relative orientation and relationship of the gene as incorporated into the recombinant plasmids pAM22, pAM25, pAM97, and pAM113 are also shown.
  • Fig. 3 is a reproduction of a radiograph showing electrophoretically separated Anaplasma marginale proteins, proteins from recombinant E coli having plasmid pAM25, proteins from E coli with plasmid pBR322, and molecular weight standard proteins.
  • Fig. 4A is a reproduction of a radiograph showing electrophoretically separated proteins including recombinant Am105, native Am105 (including Am105L and Am105U), E. coli cells containing recombinant plasmid pAM25, and E. coli cells containing plasmid pBR322.
  • Fig. 4B is a reproduction of a radiograph showing electrophoretically separated polypeptide fragments resulting from treatment of recombinant Am105, and purified native proteins Am105L and Am105U after treatment with a protease.
  • Fig. 5 is a reproduction of a radiograph showing electrophoretically separated proteins including recombinant Am105, native Am105L, and native Am105U after immunoprecipitation with monoclonal antibodies 1E, and 22B 1 , and rabbit antisera R911 and R907.
  • Fig. 6 is a reproduction of a radiograph showing electrophoretically separated proteins resulting from the surface radiolabeling and immunoprecipitation of Anaplasma marginale initial bodies using monoclonal antibodies 1E 1 and 22B 1 , and rabbit antisera R911 and R907.
  • Fig. 7A is a reproduction of a radiograph showing electrophoretically separated DNA comparing Anaplasma marginale genomic DNA versus recombinant plasmid DNA using Southern blotting.
  • Fig. 7B is a reproduction of a radiograph showing electrophoretically separated DNA comparing Anaplasma marginale genomic DNA versus bovine leukocyte DNA after treatment by restriction enzymes.
  • Fig. 8 shows four restriction enzyme maps (1)-(4) for four different geographical isolates of Anaplasma marginale indicating relevant portions of the genome containing the gene which codes for the expression of the proteins corresponding to Am105U in the Florida isolate. The identified gene areas in each map are indicated with the cross-hatched bars. Below the restriction maps are five plasmid diagrams indicating in heavy line the portion of the plasmids which incorporated part or all of the indicated genes. The portion of the plasmid not incorporating the recombinant gene DNA is shown in a light line.
  • Fig. 9 is a reproduction of a radiograph showing electrophoretically separated proteins expressed by the recombinant E. coli cell lines which incorporated the recombinant plasmids pVA1, pWAO1, plD6, and pFL10. Also shown are native proteins from the corresponding Anaplasma marginale isolates.
  • Fig. 10 is a sequence diagram showing DNA nucleotide sequences for the Florida, Virginia, Idaho and Washington isolates of Anaplasma marginale, including the genes which code for the expression of the MSP-1a or Am105U protein.
  • Fig. 11A is a reproduction of a radiograph showing DNA fragment electrophoretic separations indicating the start of transcription in the Florida isolate MSP-1a gene.
  • Fig. 11B is a sequence diagram showing portions of the DNA nucleotide sequences shown in Fig. 10 for the promoter regions of the four geographical isolates of Anaplasma marginale and E. coli.
  • Fig. 12 is a sequence diagram showing amino acid sequences for the MSP-1a (Am105U) proteins expressed by the four different geographical isolates of Anaplasma marginale.
  • Fig. 13 is a sequence diagram comparing portions of the amino acid sequences shown in Fig. 12.
  • the sequences shown in Fig. 13 indicate repeat patterns of five different types labeled A-E.
  • the number of times that a particular repeat pattern is included in the protein is indicated in the chart shown at the right of Fig. 13.
  • Fig. 14 shows a number of synthesized polypeptide sequences and whether such sequences in vitro reacted with monoclonal antibody 22B 1 .
  • Fig. 15 is a restriction enzyme map showing the cut sites for a number of restriction enzymes upon the DNA nucleotide sequence containing the gene coding for the expression of the Anaplasma marginale protein Am105L for the Florida isolate.
  • Fig. 16 is a sequence diagram showing the DNA nucleotide sequence for the gene coding for the expression of the Anaplasma marginale protein Am105L. Also shown is the corresponding amino acid sequence of protein Am105L of the Florida isolate.
  • the present invention seeks to overcome some of the limitations of the prior art by providing improved antigens and immunogens for detecting and immunizing relative to rickettsial parasites, in particular Anaplasma marginale.
  • the invention includes suitable purified antigens which are bound by serum antibodies, and which are in at least some cases immunogenic to reduce the severity or prevent infection by Anaplasma marginale and other rickettsial organisms having epitopes of the same or sufficiently similar nature.
  • the invention also includes certain monoclonal antibodies which can selectively bind antigenic components of rickettsias such as Anaplasma marginale, and provide detection and other valuable screening and diagnostic uses.
  • Selected native proteins can be isolated from Anaplasma marginale organizisms and purified or treated to produce one or more purified immunogenic polypeptides or proteins.
  • the invention includes the discovery that at least one native antigen having surface-exposed epitopes is common to numerous geographical isolates of Anaplasma marginale in forms which share conserved polypeptide sequences.
  • This protein complex has been identified and purified, and is alternatively referred to a major surface protein 1 (MSP-1) and Am105.
  • MSP-1 major surface protein 1
  • Am105U and Am105L The two component proteins of this complex are referred to as Am105U and Am105L.
  • these complexed proteins have electrophoretic mobilities which correspond to approximate molecular weights of about 105,000 daltons. In other isolates the electrophoretic mobilities and apparent molecular weights of these two complexed proteins vary, particularly with respect to one of the two complexed proteins.
  • antigenic proteins have been identified from Anaplasma marginale organisms and are characterized by electrophoretic mobilities which correspond to apparent molecular weights of about 86,000 dalto ns (Am86)6 61,000 daltons (Am61); 36,000 daltons (Am36); and 15,000 daltons (Am15). Still other antigenic proteins as identified herein are also of use in this invention.
  • the antigens and immunogens according to this invention can comprise active agents formed of one or more such proteins, polypeptide fragments of such proteins, or one or more immunologically similar proteins or polypeptides produced by polypeptide synthesis or genetic engineering.
  • Antigenic proteins of the invention are in part purified by removing or isolating Anaplasma marginale initial bodies from cellular components of the infected erythrocytes.
  • the significantly purified initial bodies are thereafter disrupted, such as by using a suitable detergent or by other means.
  • Desired antigens can be purified from the disrupted Anaplasma marginale organisms, such as by passing the disrupted initial bodies over antibodies which selectively bind the desired antigens. Such can be accomplished by passing an aqueous mixture containing the disrupted initial bodies over or through an insoluble matrix, such as an affinity chromatography column.
  • the insoluble matrix has monoclonal antibodies specific to the desired antigenic protein or peptide which recognize one or more epitopes thereon to adsorb it onto the insoluble matrix.
  • the adsorbed antigens are further purified by washing the non-adsorbed materials of the aqueous initial body mixture through the affinity chromatography column to leave the adsorbed antigens bound to the matrix.
  • the adsorbed antigens are recovered from the matrix to provide purified antigens according to this invention.
  • the novel monoclonal antibodies preferably used to prepare the purified antigens are advantageously prepared by vaccinating or otherwise inoculating mice with the appropriate rickettsial parasites, such as by injecting the mice with bovine erythrocytes infected with Anaplasma marginale. Lymphocytes are taken from the spleen of the infected mice. The lymphocytes from the mice are fused with immortal cells, such as myeloma cells, to produce hybridoma cells which are cloned to develop hybridoma cell lines. Some of the hybridoma cell lines produce monoclonal antibodies which will selectively bind to the desired antigens. The collection of hybridoma cell lines are then screened using a novel approach to identify the hybridomas of interest.
  • the screening of the hybridomas can advantageously initially include procedures for detecting the hybridomas which produce antibodies which bind to Anaplasma marginale. This is advantageously accomplished by indirect immunofluorescence on smears of Anaplasma marginale-infected blood.
  • the hybridomas are then further screened to determine those which produce monoclonal antibodies against specific Anaplasma marginale proteins, such as by immunoprecipitation of selected proteins of Anaplasma marginale by the cell line supernatants containing the monoclonal antibodies.
  • Additional amounts of the desired monoclonal antibodies are advantageously produced by collection of ascitic fluid from mice inoculated with the selected hybridoma cell lines.
  • a monoclonal antibody collected from murine ascitic fluid is appropriately purified, such as by precipitation, dialysis and chromatography.
  • the purified monoclonal antibody is then coupled to an insoluble matrix such as Sepharose to prepare an immunoaffinity matrix.
  • Partially purified disrupted rickettsial organisms, such as Anaplasma marginale initial bodies, are then passed through the immunoaffinity matrix and the desired antigenic protein is selectively adsorbed onto the matrix.
  • the purified protein which has adsorbed onto the matrix is then appropriately removed or otherwise recovered from the matrix to provide significant amounts of the desired antigen in a sufficiently purified form to serve effectively in the indicated uses for this invention.
  • the degree of purity of the proteins achieved in accordance with the present invention is dependent upon the method of production used.
  • the purity of native proteins and polypeptides derived therefrom is significantly higher than the purity of the antigen in its natural state.
  • Am105 in its natural state Am105 is believed to be present in an amount of about 0.1 to 1% of the total protein present in the initial bodies. In its natural state, many other impurities such as about 200 other proteins, carbohydrates, red cells, glycoproteins, and nucleic acid are present. However, the Am105 can be purified to significantly higher levels of purity using the methods taught herein. Purity levels of approximately 10% by weight or higher are believed operable. Purity levels of 20% by weight or higher are more preferred. Still more preferred are purity levels of 50% by weight or higher.
  • the purification techniques taught herein are capable of producing purity of at least 90 weight percent, preferably at least 95 weight percent and most preferably at least 98 weight percent.
  • the purified Am105 has a molecular weight of about 105,000 daltons as measured by electrophoretic mobility analysis but significantlv les when molecular weight is determined by DNA and amino acid sequence information as presented herein.
  • Other antigens according to this invention are expected to also show significant differences between molecular weight measured by electrophoretic mobility versus sequenced information. Nonetheless the electrophoretic mobility information provides a valid means for identifying and isolating the antigens according to this invention.
  • One of the demonstrated immunogenic antigens of this invention is reactive with monoclonal antibodies produced by hybridomas cell lines ANA 15D2 and ANA 22B1. Deposits of cell lines ANA 15D2 and ANA 22B1 have been made in the American Type Culture Collection under ATCC Nos. HB9046 and HB9047, respectively.
  • immunoaffinity purified antigens of this invention such as Am105
  • the recombinant or artificially synthesized peptides as taught herein are most preferably substantially free of contaminating glycoproteins, carbohydrates, red cells, and nucleic acids.
  • Active fragments or subunits of the identified antigenic polypeptides of this invention may be effective in inducing immunity to Anaplasma marginale or other rickettsial organisms. Effectiveness of at least some of the antigens has been demonstrated in cattle.
  • the size of the active fragment(s) may be as small as six to twenty or possibly six to ten amino acids.
  • the antigens according to this invention can be produced by immunoaffinity chromatography as described above and elsewhere herein, or using artificial methods of polypeptide synthesis, or using genetic engineering with expression of the desired peptide(s) or protein(s).
  • the invention further includes certain novel genetically engineered DNA and RNA sequences and microorganisms incorporating such sequences which have been produced for the purposes of analyzing and expressing the novel antigens according to this invention.
  • Such recombinant microorganisms were advantageously produced by creating a pseudo-random genomic library of recombinant bacteria, such as E. coli, which incorporate novel recombinant DNA plasmids.
  • the recombinant plasmids incorporate DNA fragments from the genome of an appropriate rickettsial parasite, such as Anaplasma marginale.
  • the recombinant DNA plasmids were created by cleaving plasmid DNA with a suitable restriction enzyme.
  • Anaplasma marginale DNA is cleaved with suitable restriction enzymes to produce a large number of various Anaplasma marginale DNA fragments.
  • the DNA strands from the plasmids and Anaplasma marginale were mixed to join fragments of each and then ligated to form recombinant plasmid vectors.
  • the recombinant plasmid vectors were implanted into suitable hosts, E. coli, and cloned to produce a collection of recombinant bacterial cell lines.
  • the resulting recombinant cell lines were screened for the expression of desired antigens, such as by using selected monoclonal antibodies against the parasites, as described above and elsewhere herein.
  • viruses such as vaccinia virus can be used to produce recombinant viral vectors bearing nucleic acid sequences coding for the expression of the desired antigens.
  • Recombinant RNA can alternatively, be produced to code for the expression of the desired antigens.
  • Recombinant bacterial cell lines were developed which express antigenic recombinant proteins which mimic the surface-exposed native proteins contained in the protein complex alternatively called MSP-1 and Am105.
  • the invention also includes the discovery that the native proteins contained in this complex are polymorphic between different geographical isolates of Anaplasma marginale varying in size and amino acid sequences.
  • Recombinant plasmids containing Anaplasma marginale DNA were analyzed to determine the DNA sequences associated with the expression of these related polymorphic proteins.
  • the antigens expressed by these four geographical isolates were also analyzed to determine the amino acid sequences. The antigens were found to have a hypervariable domain of variable numbers of tandemly repeated sequences at the N end of the polypeptide.
  • tandem repeats consisted of polypeptides of 28 or 29 amino acids.
  • the number of repeats varied between 2 and 8 within the group of 4 different isolates analyzed. However, all of the tandem repeats in the four isolates were found to possess conserved amino acid sequences.
  • Monoclonal antibodies which bind to surface-exposed epitopes of Anaplasma marginale and are effective at neutralizing the infectivity of such organisms also bind to at least some of the conserved epitopes contained in the tandem repeat regions of the proteins.
  • Novel recombinant cell lines have been developed which express proteins including the tandem repeat polypeptide sequences. Such nove recombinant-produced proteins containing the conserved polypeptid sequences have been demonstrated to cause an immune response in cattle which is effective to reduce the severity or prevent acute infection by Anaplasma marginale.
  • Other antigens bound by selected monoclonal antibodies which are reactive with Anaplasma marginale, particularly those reactive with epitopes shown to cause neutralization of the infectivity of the parasites are also within the scope of this invention.
  • the immunogenic antigens according to this invention can be used in vaccines to bring about an immune response effective to reduce the severity or prevent infection by rickettsial organisms.
  • Such antigens should be present in a single dose of the vaccine in an amount of approximately 1-1000 micrograms, preferably 5-400 micrograms, and most preferably 10-200 micrograms.
  • a single injectable dose will usually have a volume of about 1-2 milliliters. Therefore the concentration of purified surface antigen in an injectable vaccine composition will usually be in the range of from about 1 to about 500 microgram s/milliliter and preferably about 5 to about 200 micrograms/milliliter and most preferably 10-500 micrograms/milliliter.
  • the antigens can advantageously be dissolved or otherwise administered with an adjuvant, such as Freund's complete and/or incomplete adjuvants.
  • the vaccine in addition to containing the purified antigens and optionally an adjuvant, may also contain any other suitable pharmaceutically acceptable carrier or diluent.
  • the pharmaceutically acceptable carrier or diluent is a compound, composition or solvent which is preferably a non-toxic sterile liquid useful for administrauon of the active antigens or in some cases otherwise increasing the effectiveness of the inoculation treatments.
  • a vaccine comprising the purified antigens and any desired adjuvants and diluents.
  • the antigens can be purified from the parasites, produced as expressed polypeptides or proteins fro m recombinant cells, or produced by artificial polypeptide synthesis.
  • Such purified antigens are preferably added to a suitable pharmaceutically acceptable carrier or diluent, and any desired adjuvant(s).
  • the animals are successively inoculated with a single dose as defined above at one to six week intervals, preferably two to four we ek intervals about two to eight times, preferably three to five times.
  • the purified protein(s) or polypeptide(s) should be present in the vaccine in an amount(s) effective to induce an immune response in the animals being treated.
  • Such immune response is preferably sufficient to protect the vaccinated animals so that if subsequently challenged with virulent rickettsias, such as Anaplasma marginale, the degree of acute infection is substantially reduced or even prevented. Injection will usually be performed intramuscularly (i.m.) or subcutaneously (s.c).
  • the purified recombinant, synthesized, or native polypeptides and proteins defined herein also are useful in diagnostic tests to determine whether an animal is infected by an applicable rickettsial parasite, such as Anaplasma marginale. Conversely, such diagnostic tests may also incorporate one or more of the monoclonal antibodies specific to infection by such organisms.
  • the diagnostic tests are advantageously immunoassays, such as one or more types of enzyme linked immunosorbent assays, such as for serologic diagnosis of anaplasmosis.
  • the assays can be radioimmunoassays or others utilizing the selective binding of the purified antigens to antibodies raised in an infected animal, or monoclonal antibodies which specifically bind antigens associated with the particular parasitic organisms of interest. When samples from subject animals are tested using such antigens and/or antibodies, results distinguishing infected and non-infected animals are obtainable.
  • the discovered DNA sequence information can be used to create novel nucleic acid sequences which are useful as a nucleic acid probe which can be labelled and used to detect for the presence of hybridizing DNA or RNA, to provide a diagnostic test of great sensitivity.
  • mice Animals - Young Hereford and Holstein cattle were used. Animals to be infected with Anaplasma marginale were splenectomized. Two inbred strains of mice, BALB/c and B10.A(3r), were used as a source of cells to make hybridomas. These and additional strains, B10.A, B10.A(5R) and B10.A(2R), were used as a source of thymocytes for co-culture as feeder cells with hybridoma cells.
  • mice were given an intravenous booster injection of 0.2 ml of lysate.
  • the second preparation a lysate of infected erythrocytes, was purified on a Renografin density gradient (25-55%) as described in Davis, N.C. et al, Infec Immun. 22:597-602 (1978).
  • the bands containing anaplasma bodies and contaminating erythrocyte stroma were collected and washed, as described above, then resuspended in 10 ml of HBSS.
  • Five BALB/c mice were injected intraperitoneally with 1 ml for primary immunization and intravenously with 0.2 ml for booster immunization as described. All mice were immunized at least three weeks before receiving a booster injection.
  • HAT hyperxanthine, aminopterin and thymidine
  • NS1 a cell line that produces, but does not secrete K light chains, Oi et al, V.T., In Selected Methods in Cellular Immunology (Eds.) B.B. Mishell and SM Shiigi, WH Freeman and Co., pp. 351-372 (1980) and SP2/O-Ag14, a cell line derived from a Nsl-BALB/c hybrid that synthesizes neither light or heavy chains, Schulman, M.
  • DMEM Dulbecco's Modified Eagle Medium
  • FCS fetal calf serum
  • 2ME 2-mercaptoethanol
  • penicillin 100 units/ml
  • streptomycin 100 g/ml
  • Spleen cells were obtained from the freshly-killed, immunized mice by injecting the spleen with DMEM, gently tearing it apart with tweezers and then pressing it through a 100 mesh screen into a 50 ml test tube. Following removal of particulate debris, the cells were centrifuged into a pellet and the medium removed. Contaminating mouse erythrocytes were selectively lysed by brief exposure to distilled water (2 ml) and the spleen cells were then quickly diluted in DMEM. Thymocytes to be used as feeder were collected as above (but without water lysis) and suspended in DMEM-FCS-HAT at 1 x 10 7 cells per ml.
  • Myeloma cells and spleen cells were counted, then mixed either at a ratio of 5 or 15 spleen cells to 1 myeloma cell. Usually, 10 8 spleen cells were mixed with 2 or 4 x 10 7 myeloma cells. The cell mixture was sedimented and the supernatant removed. One ml of a 50% solution of polyethylene glycol (PEG 1540, Baker Chemical Co.) was then placed over the cell pellet and slowly mixed with the cells so as to form a slurry of small (1 mm 3 ) clumps of cells. Following 3 minutes of mixing, the cells were slowly diluted by adding 10 ml DMEM in 10 minutes and 20 ml over the next 5 minutes.
  • PEG 1540 polyethylene glycol
  • the resultant mixture of fused cells was centrifuged into a pellet and the cells were resuspended in DMEM-FCS-HAT. Thymocytes were then added to give a mixture containing 10 8 spleen cells, tumor cells and 1 x 10 9 thymocytes. Cells were distributed in ten 96-well culture plates and placed in the incubator. One half the tissue culture medium was replaced every 3 to 4 days. When clones of hybridomas were 300- 1000 cells in size (usually by 12-18 days), the supernatants were collected and tested by indirect immunofluorescence on smears of infected erythrocytes. Cells from positive wells were identified and transferred to 24-well (2ml) culture plates.
  • DMEM-FCS-HT Three to 5 x 10 6 thymocytes were added as feeder cells to support growth. At 14 days or when the cultures needed to be thinned, the medium was replaced with DMEM-FCS-HT. The cells were maintained in static cultures (1 week in DMEM-FCS-HT then on DMEM-FCS) for two weeks by removing excess cells and feeding every 2-4 days, depending on the rate of replication of individual clones. At this time, a duplicate plate was prepared and allowed to overgrow. The supernatants from this plate were tested for antibody activity. All cell lines identified as antibody producers by this procedure were then taken from the master plate and expanded into 6 well plates (5 ml capacity in each well) as single cultures, 3 wells per cell line. Cells were collected twice and frozen (3-10 x 10 6 cells in 10% DMSO) in liquid nitrogen. The remaining cells were allowed to proliferate and die. The supernatants were then collected (approximately 15 ml) and frozen for subsequent analysis.
  • cell lines producing antibody of immediate interest were taken from the freezer, thawed and cloned by limiting dilution immediately or following 24-hrs. culture.
  • hybridoma cells were plated in 2 to 6 96-well plates, 3 cells per well in the presence of 10 6 thymocytes.
  • Wells containing single colonies were identified microscopically and supernatants were collected and tested for antibody activity.
  • Cells from positive wells were transferred as above to 24-well plates and then to 6-well plates for colony expansion and preservation. Four to 6 cloned lines were preserved for each line.
  • the hybridoma cell supernatants are initially screened for anti-Anaplasma marginale antibody by indirect immunofluorescence on acetone-fixed smears of Anaplasma marginale infected blood.
  • the positive (antibody producing) cell lines are then further screened for specific production of anti-Am105 antibodies using immunoprecipitation of either [ 35 S] methionine radiolabeled or [ 125 I] surface radiolabeled Anaplasma marginale.
  • the exact procedure for this which is a slight modification of the procedure reported by Palmer, G.H. et al, J. Immunology, 133:1010 (1984), is as follows.
  • the immunoprecipitation of surface-radioiodinated initial bodies and erythrocyte stroma was performed by using a modification of the technique described by Shapiro, S.Z. et al, J. Immunol. Methods, 13:153 (1976).
  • the initial bodies or erythrocytes were disrupted with 1% (v/v) Nonidet P-40 and 0.1% (w/v) SDS at 4°C for 30 min, centrifuged at 135, 000 x G for 60 min, passed through a 0.2 m filter (Millipore Corp., Bedford, MA), and sonicated for 15 sec at 50 W.
  • the immunoprecipitates (2000 to 10,000 cpm) and the radioiodinated initial bodies and erythrocytes (200,000 cpm) were electrophoresed on 7.5 to 17.5% (w/v) gradient polyacrylamide gels.
  • the gels were fixed in glass-distilled water:methanol:acetic acid (6:4:1), were dried, and were exposed to Kodak X-Omat AR film (Eastman-Kodak, Rochester, NY) at room temperature for 48 hr to identify the radioiodinated initial body and erythrocyte polypeptides, and at -70°C by using Cronex Quanta III intensifying screens (DuPont, Wilmington, DE) for 72 hr to identify the immunoprecipitates.
  • Two cell lines (ANA 15D2 and ANA 22B1) were identified that produced anti-Am105 antibodies.
  • the cell lines were double cloned and the supernatants concentrated to 0.1 mg immunoglobulin/ml following determination of isotype (both were IgG3).
  • the concentrated supernatants were used for all further testing.
  • the immunoprecipitation of 125 I-Am105 was repeated with the double cloned hybridoma supernatants.
  • Am105 is an initial body protein and not of erythrocyte origin includes unreactivity of ANA 15D2, ANA 22B1, or rabbit anti-Am105 antibodies (all positive on initial bodies in infected erythrocytes) with uninfected erythrocytes or infected erythrocyte membranes using immunofluorescence, and failure of these antibodies to immunoprecipitate 125 I radiolabeled erythrocyte ghosts. Additionally, ANA 15D2 AND ANA 22B1 immunoprecipitate Am105 metabolically radiolabeled in vitro during short term erythrocyte culture. It has been demonstrated that during short term cultures 35 S incorporation occurs exclusively in initial bodies.
  • Am105 is immunoprecipitated as a doublet band seen most clearly with 35 S labelled Am105 or silver stained Am105.
  • the doublet is consistently present and has been found to be indicative of a complex of two Anaplasma marginale proteins having surface-exposed epitopes.
  • the two proteins as a complex are herein sometimes referred to as Major Surface Protein 1 (MSP-1) as well as the term Am105.
  • MSP-1 Major Surface Protein 1
  • Am105U and Am105L The protein Am105U is also sometimes referred to as MSP-1a with the Am105L sometimes referred to as MSP-1b.
  • the proteins forming the complex have electrophoretic mobilities which are very nearly the same.
  • Am105U has electrophoretic mobility corresponding to molecular weight of approximately 105 kilodaltons. Some measurements have indicated the electrophoretic mobility of Am105L is more nearly 100 kilodaltons. These mobilities are associated with the proteins of the MSP-1 or Am105 complex for the Florida geographical isolate of Anaplasma marginale. As further described below the corresponding proteins for other geographical isolates of Anaplasma marginale show a high degree of polymorphism in the proteins which make of the MSP-1 complex. Accordingly, the electrophoretic mobilities of the proteins forming this complex vary. However, the antigenic nature of these different isolates is similar as will be explained hereinafter. Monoclonal antibodies can in general be prepared against other antigenic surface proteins of Anaplasma marginale using procedures the same as or similar to those described above. To date hybridoma cells producing monoclonal antibodies have been created against additional antigenic surface proteins of Anaplasma marginale.
  • the mechanism of neutralization by the anti-Am105 monoclonal antibodies is unknown at present. Certainly monoclonal antibodies directed against an initial body determinant necessary for erythrocyte receptor binding would neutralize infectivity. ANA 15D2 and ANA 22B1 may recognize the same or overlapping determinants as they reciprocally inhibit binding of each other to 125 I-Am105 in a competition radioimmunoassay. Other modes of neutralization include agglutination and when possible across murine-bovine species lines, interaction with bovine effector cells and complement-fixation with initial body lysis.
  • Am105 as a protective immunogen to prevent bovine anaplasmosis would require that the determinants recognized by the neutralizing monoclonal antibodies be common to all isolates in a given region. Both similarities and differences in protein and antigenic composition among various isolates of Anaplasma marginale have been demonstrated. Six isolates from widely geographically separated areas of the U.S. (Florida; Okanogan, Washington; South Idaho; North Texas; Clarkston, Washington; Virginia) have been examined for the presence of determinants recognized by ANA 15D2 and ANA 22B1 using indirect immunofluorescence on acetone fixed blood smears.
  • the determinants were present on 100% of the initial bodies (as determined by comparison with Wright's stained initial bodies in an adjacent section of the smear) in all six isolates. Additionally, the determinants were present at all stages of a primary, acute infection from 1% parasitemia through peak parasitemia with hemolytic crisis. The presence of thee determinants now identified as protective antigens on multiple isolates and their presence at all stages of infection fulfill important criteria for use of Am105 or its fragments as a vaccine. Am105 and Am105 polypeptides containing determinants recognized by the neutralizing monoclonal antibodies have been tested as effective immunoprophylaxis for bovine anaplasmosis.
  • Probability values (p) are calculated using the pooled t-test; p values of less than 0.05 are considered significant NS, not significant. ND, significance not determined.
  • the results of a test using two cell lines designated ANA 15D2 and ANA 22B1 which produce monoclonal antibodies to Am105 and a cell line TRYP 1E1 which produced monoclonal antibodies against Trypanosoma brucei are reported in Table 2. These results indicate that by using 10 10 initial bodies partial neutralization was observed as judged by a significant prolongation of the prepatent period.
  • the steps for purifying the monoclonal antibodies to couple to the immunoadsorbent column are:
  • BALB/c X BIO A mice were injected intraperitoneally with 1.0 ml Pristane (Aldrich Chemical Co., Milwaukee, WI) and one week later with 2-3 X 10 6 double cloned hybridoma cells. Ten days later, ascitic fluid with withdrawn from the mice, centrifuged at 1,675 X G to pellet insoluble debris and passed over a glass wool column.
  • a 50% (v/v NH 4 SO 4 precipitation is conducted on the wo ol column effluent and following resuspension in .032M Tris is dialyzed for 24 hrs. against .032M Tris.
  • This dialyzed sample is chromatographed on a DE-52 cellulose column and eluted using a 0-0.2M NaCl continuous gradient in .032M Tris.
  • the eluted fractions are titere d using indirect immunofluorescence on acetone-fixed smears of Anaplasma marginale infected blood.
  • the purity of the antibody is determined using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) with detection of protein using Coomassie Blue staining.
  • the purified monoclonal antibody, ANA 15D2 (pure by Coomassie Blue staining on SDS-PAGE) is dialized against 0.1M NaHCO 3 , 0.5M NaCl pH 8.3.
  • the dialized protein is coupled to CNBr-activated Sepharose 4B (Pharmacia Fine Chemicals, Piscataway, NJ.) at 10mg protein/ml settled Sepharose 4B overnight at 4oC by rotation.
  • the coupled immunoaffinity matrix (ANA 15D2-Seph 4B) is poured into an Econo Column 11.5 ml column Bio-Rad Lab., Richmond, CA) and stored at 4oC until use.
  • Anaplasma marginale has never been successfully grown in long-term in vitro culture.
  • the source of Anaplasma marginale therefore is blood of infected, splenectomized calves.
  • the calves are inoculated with 10 10 initial bodies intramuscularly and then checked daily for evidence of parasitemia using Wright's stained blood smears.
  • the percentage of infected erythrocytes reaches 40-95%, 4-7 liters of blood are collected into 4 units/ml heparin sulfate.
  • the erythrocytes are washed 3X with phosphate buffered saline, pH 7.2 and then resuspended 1:1 in 31.2% dimethylsulfoxide in phosphate buffered saline. This suspension is frozen in liquid nitrogen and constitutes the Anaplasma marginale initial body source.
  • Anaplasma marginale infected erythrocytes (10 12 will yield approx. 1.0 mg pure Am105) are thawed from liquid nitrogen at 37°C and washed 5X in phosphate buffered saline using centrifugation at 27,000 X G. The sediment is resuspended in 35 ml phosphate buffered saline, disrupted by 2 min. of sonication at 50 watts (127 X 4 mm titanium probe, Braun-sonic 1510, Braun Instruments, San Francisco, CA) and then washed two times at 1650 X G for 15 min.
  • the purified initial bodies are disrupted in 5 ml 50mM Tris-HCl (pH 8.0, 1.0% Nonidet P40, 0.1% sodium dodecyl sulfate, 5mM EDTA, 5mM iodoacetamide, ImM phenlmethylsulfonylfiuoride, 0.1 mM tosyl-L-lysyl chloromethane) and applied to the ANA 15D-Sepharose 4B monoclonal immunoaffinity column.
  • Tris-HCl pH 8.0, 1.0% Nonidet P40, 0.1% sodium dodecyl sulfate, 5mM EDTA, 5mM iodoacetamide, ImM phenlmethylsulfonylfiuoride, 0.1 mM tosyl-L-lysyl chloromethane
  • the ANA 15D2-Sepharose 4B monoclonal immunoaffinity column is washed with 100 X column volume with TEN buffer (20mM Tris-HCl, 5mM EDTA, 0.1 M NaCl, 25mM NaN 3 , pH 7.6) 1% NP-40, 0.1% SDS and then approximately 10 12 disrupted initial bodies are loaded onto th e column at a rate of 25 ml/hr.
  • the unbound proteins are washed out using 100 X column volume TEN with 1.0% NP-40 and 0.1% SDS and then any remaining unbound proteins and the NP-40, SDS (nondialyzable detergents) are removed by 100 X column volumes TEN without detergent
  • the specifically bound Am105 is eluted using 50mM Tris pH 8.0 with 0.5% deoxycholate and 2M KSCN. Recovery of Purified Surface Antigen.
  • the eluted protein (Am105) is dialyzed against phosphate buffered saline to remove the KSCN and deoxycholate. Am105 is quantitated using a modified Lowry protein assay and frozen at -70°C until use. Preparation of Vaccine.
  • Am105 is thawed and suspended in Freund's incomplete adjuvant to produce a vaccine in which purified antigen, such as Am105, is present in an amount of 10, 25 or 100 micrograms/milliliter.
  • Groups comprised of 5 Holstein calves, weighing approximately 100kg, were immunized 4 times with 100 g of either ovalbumin emulsified in Freund's complete adjuvant (group 1), Am105 emulsified in Freund's incomplete adjuvant (group 2), or Am36 emulsified in Freund's incomplete adjuvant (group 3).
  • the immunizations were conducted on day 1, day 17, day 35 and day 59.
  • Group 4 which consisted of 4 calves, was not immunized.
  • the antibody response of the 4 groups to Am105 was determined using a radioimmunoassay based on 125 I-Am105.
  • the calves were challenged on day 83 with 10 8 purified Florida isolate A. marginale initial bodies. The calves were monitored for infection by daily clinical examination, determination of hematocrit, and examinatien of Wright's stamed bleed smears for presence of parasites. The results are presented in Table 4.
  • Anaplasma marginale initial body surface proteins and protein complexes identified to date each have a surface exposed epitope on the initial body.
  • Evidence for the surface nature of Am105, Am86, Am61, Am36, Am31, and Am15 proteins was obtained by radioiodination of the proteins on intact initial bodies using a membrane impermeant radiolabeling technique (lactoperoxidase) (Palmer, GH, McGuire TC: J. Immunol 133:1010-1015, 1984).
  • Anaplasma marginale initial bodies were purified from parasitized erythrocytes by using ultrasonic disruption and differential centrifugation.
  • the initial bodies were intact as determined by electron microscopy, were not agglutinated by anti-bovine erythrocyte sera and were infective.
  • the initial body proteins surface radioiodinated using lactoperoxidase included Am220, Am105 complex, Am105U, Am105L, Am86, Am61, Am56, Am42, Am36, Am31 and Am25. Of these Am105, Am105U, Am105L, Am86, Am61, Am36 and Am31 are precipitated by neutralizing antibody.
  • the latter group of proteins are major surface proteins and one or more of these proteins alone or in combination might be incorporated in a vaccine or diagnostic test
  • the data presented in Table 4 shows that either purified Am105 or Am36 will induce protective immunity against virulent Anaplasma marginale challenge in calves. That purified proteins will work as vaccines indicates that similar results might be achieved with synthetic peptides of 6 amino acids or more mimicking the antigenic structure of the biologically active epitopes, with antigens expressed in heterologous bacteria containing the genes coding for the biologically active epitopes of the surface proteins or with one or more antigens expressed in virus vectors containing the genes coding for biologically active epitopes of the surface proteins.
  • Anaplasma marginale initial body surface proteins bear epitopes recognized by neutralizing antibody.
  • Antiserum prepared by immunization of rabbits with purified Anaplasma marginale initial bodies completely neutralized the infectivity of 10 10 purified initial bodies for splenectomized cattle.
  • these proteins were recognized by the neutralizing antibody, demonstrating their potential roles, either individually or in combination, in inducing neutralizing antibody and therefore their use as an improved vaccine for cattle.
  • the recognition of these surface proteins was consistent regardless of the isolate (Florida, Washington-O, Virginia) of used to immunize the rabbits to prepare the antiserum.
  • Am105, Am105U, Am105L and Am36 each bear an epitope common among Anaplasma marginale isolates tested (Florida, Washington-O, Washington-C, Virginia N. Texas, S. Idaho, Kansas, Oklahoma, Kapiti (Kenya), and Israel-round and Israel-tails) and to Anaplasma principal (a less virulent species) that are capable of inducing neutralizing antibody.
  • Anaplasma marginale isolates tested Florida, Washington-O, Washington-C, Virginia N. Texas, S. Idaho, Kansas, Oklahoma, Kapiti (Kenya), and Israel-round and Israel-tails
  • Anaplasma marginale isolates tested Florida, Washington-O, Washington-C, Virginia N. Texas, S. Idaho, Kansas, Oklahoma, Kapiti (Kenya), and Israel-round and Israel-tails
  • Anaplasma marginale isolates tested Florida, Washington-O, Washington-C, Virginia N. Texas, S. Idaho, Kansas, Oklahoma, Kapiti (Kenya), and Israel
  • the Am105, Am105U, Am105L or Am36 epitopes are completely protease sensitive and do not bear any carbohydrate residues and as such can be easily mimicked by short (minimum 6 amino acid s) synthetic peptides or by polypeptides expressed in a foreign bacterium or virus containing the gene coding for the epitopes.
  • short (minimum 6 amino acid s) synthetic peptides or by polypeptides expressed in a foreign bacterium or virus containing the gene coding for the epitopes.
  • the availability of monoclonal antibody makes both the synthetic peptide and the gen e cloning procedures alternative approaches to vaccine development as is explained more fully below.
  • the surface proteins Am105, Am105U, Am105L, Am86, Am61, Am36, Am31, Am13 identified to date are specifically recognized by serum taken from cattle over a period of 30 days to 255 days post-infection. This recognition is consistent regardless of the isolate used to infect the cattle (Florida, Virginia, N. Texas). This specific recognition is required for selection of Anaplasma marginale proteins to be used individually or in combination as the antigen in an improved serologic assay to diagnose anaplasmosis in cattle. These supporting data point to use of these proteins for diagnosing anaplasmosis. The isolation and incorporation of these proteins into a serologic assay for diagnosis is a straightforward technical procedure. The findings to date also indicate potential use of a synthetic peptide of 6 amino acids or more or a polypeptide expressed in a vector organism as immunologically equivalent agents for diagnostic purposes.
  • Am105 and Am36 isolated by monoclonal immunoaffinity chromatography and coated into wells of a microtiter plate at 5 to 100 ng/well, have been tested as the basis of an Enzyme Linked Immunosorbent Assay (ELISA) for serologic diagnosis of anaplasmosis.
  • ELISA Enzyme Linked Immunosorbent Assay
  • Each assay has been found capable of differentiating non-infected from Anaplasma marginale or Anaplasmaloid infected cattle at periods from 30-255 days post-infection and was accurate regardless of the isolate used to infect the -attle (Florida, N. Texas, Virginia, Washington-O, Washington-C, Idaho, Kenya, Israel-round, Israel-tailed).
  • the present serologic assay is based on the isolated whole Am105 or Am36.
  • Proteins of 105,000 daltons (Am105), 86,000 daltons (Am86), 61,000 daltons (Am61), 31,000 daltons (Am31) and 15,000 daltons (Am15), all identified as surface proteins, are stron antigenic as evidenced by antibody in Anaplasma marginale-infcctcd cattle.
  • dilutions of the post-infection sera have high titers to Am86 and Am1 5 throughout infection, indicating a preferential response.
  • Use of Am86 alone or in combination with Am105, Am61, Am31, or Am15 as aan antigen in a diagnostic test is implied from these findings.
  • Am105 consists of a complex of two noncovalently Knked polypeptides of similar molecular weight
  • Am105U and Am105L are products of separate genes, and to examine the structural and antigenic relationships between the polypeptides, we cloned and expressed genes coding for Am105L epitopes in Escherichia coli.
  • Am105U and Am105L as separate gene products, each bearing surface-exposed epitopes. Cloning and expression of Am105L will allow determination of its efficacy as a single, non-complexed immunogen.
  • Mouse monoclonal antibodies were prepared as described before (14, 17) and designated as follows: 1E 1 and 24A 1 , control antibodies to a surface glycoprotein of Trypanosoma brucei; F19E, an antibody that immunoprecipitates Am36 (19); 15D 2 and 22B ⁇ , antibodies that immunoprecipitate Am105 and neutralize infectivity of Anaplasma marginale in vitro (17); and F34C 1 , an antibody that immunoprecipitates Am105.
  • Antisera to Am 105 (17), to isolated Anaplasma marginale initial bodies (19), and to E. coli containing pBR322 or pAM25 plasmid DNA were made in rabbits. Rabbits were immunized four times with lysed bacteria (2 x 10 9 organisms in complete Freund adjuvant for the first immunization, and 10 10 organisms in incomplete adjuvant for the other three). Titers were evaluated by an enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (3), or immunoprecipitation of [ 35 S]methionine-labeled extracts of Anaplasma marginale(2).
  • ELISA enzyme-linked immunosorbent assay
  • radioimmunoassay (3) radioimmunoassay
  • rabbit antisera are designated as follows: R612, a control antibody prepared against a surface glycoprotein of Tbrucei; R781, an antibody prepared against isolated initial bodies of Anaplasma marginale; R873 and R874, antibodies prepared against Am105 isolated by immunoaffinity chromatography on monoclonal antibody-Sepharose 4B (17) purified Am105 consists of Am105U and Am105L); R907, an antibody prepared against E. coli(pBR322); and R911, an antibody prepared against E. co/ ⁇ (pAM25).
  • Antigen detection on nitrocellulose filters Proteins of Anaplasma marginale or recombinant E. coli were bound to nitrocellulose filters and detected by reaction with specific antisera and 125 I-labeled protein A as described by Young and Davis (26), with two modifications: (i) after chloroform lysis, filters were fixed in 10% acetic acid-25% isopropanol; and (ii) 1% hemoglobin was added to buffers instead of bovine serum albumin to block nonspecific binding of 12S I-labeled protein A to the filters.
  • ELISA- ELISAs were as described by Ellens and Gielkens (6), using Am105 attached to plates at 50 ng per well.
  • the enzyme label was horseradish peroxidase-protein A, and the substrate was recrystallized 5-aminosalicylic acid.
  • Am105 was isolated from Anaplasma marginale by immunoaffinity chromatography on monoclonal antibody 15D 2 -Se ⁇ harose 4B (17) and consisted of Am105U and Am105L. Sera against Am105 and against E. coli containing pBR322 or pAM25 were prepared in rabbits. Immunoprecipitation.
  • Anaplasma marginale organisms were radiolabeled by metabolic incorporation of [ 35 Sjmethionine during short-term in vitro culture (2) or by surface radioiodination, using lactoperoxidase (19). E. coli organisms were also labeled with 35 S during exponential growth in 1-ml cultures containing 250 Ci of [ 35 S]methionine and 35 g of ampicillin per ml.
  • organisms were solubilized by sonication at 4°C in a lysis buffer consisting of 50 mM Tris hydrochloride (pH 8.0), 5 mM EDTA, 5 mM iodoacetamide, 1 mM phenylmethylsulfonyl fluoride, 0.1 mM N-tosyl-L-h/sine chloromethyl ketone, 0.1% (wt/vol) sodium dodecyl sulfate (SDS), and 1% (vol/vol) Nonidet P-40.
  • a lysis buffer consisting of 50 mM Tris hydrochloride (pH 8.0), 5 mM EDTA, 5 mM iodoacetamide, 1 mM phenylmethylsulfonyl fluoride, 0.1 mM N-tosyl-L-h/sine chloromethyl ketone, 0.1% (wt/vol) sodium dodecyl sulfate (
  • the solubilized extract was centrifuges at 130,000 x g for 1 h at 4oC and passed through a 0.2- m-pore-size filter (Centrex; Schleicher & Schuell, Inc.) before being used for immunoprecipitation with rabbit or mouse antibodies and protein A-bearing Staphylococcus aureus (Calbiochem)(9, 17, 23).
  • the precipitated radiolabel was eluted and analyzed on 7.5 to 17.5% polyacrylamide-SDS gels, 7.5% polyacrylamide gels containing 4M urea, or 5% polyacrylamide gels containing 4 M.
  • 14 C-labeled standard proteins were as follows (molecular weight): myosin (200,000), phosphorylase b (92,500), bovine serum albumin (69,000), ovalbumin (46,000), carbonic anhydrase (30,000), and lysozyme (14,300).
  • Bovine blood infected with Anaplasma marginale at >50% erythrocytic parasitemia, was washed four times with phosphate-buffered saline. At each wash an upper layer containing leukocytes and erythrocytes was removed. The remaining erythrocytes were then frozen in phosphate-buffered saline at a packed cell volume of 50%. A 100-ml volume of the erythrocyte suspension was thawed and centrifuged at 30,000 x g for 20 min at 4°C to pellet Anaplasma marginale initial bodies and erythrocyte membranes.
  • the pellet was washed a further three times in phosphate-buffered saline at 30,000 x g to remove hemoglobin from the lysed erythrocytes.
  • DNA was then extracted from initial bodies (11) and further purified by deproteinization with phenol- chloroform, digestion with RNase A and proteinase K, and precipitation with ethanol.
  • Anaplasma marginale DNA was partially digested with Sau3A to an average size of 5 kilobases (kb). Digested DNA was ligated with BamHi-cleaved and dephosphorylated pBR322, using T4 DNA ligase (25). E. coli HB101 cells were transformed to ampicillin resistance by the high-efficiency transformation protocol and Hanahan (8). Plasmids pAM22 and pAM25 were identified by expression screening of a library containing 8,000 recombinants with R873 serum (rabbit anti-[Am105U plus Am105L] complex). Other colonies in this library, such as that containing pAM14, also reacted with R873 and contained the pAM22 sequence plus various lengths of additional DNA that extended beyond the Bglll sites.
  • a second library of 3,000 recombinants was prepared by digesting Anaplasma marginale DNA to completion with Bglll and ligating into the BamHI site of pBR322. Clones containing pAM97 and pAM113 were identified in this library by expression screening with R873.
  • Hybridization was at 65°C in 5x SSPE (0.18 M NaCl, 0.01 M NaH 2 PO 4 , 0.001 M EDTA [pH 7.4])-0.25% Sarkosyl (Sigma) containing 10% dextran sulfate, 100 g of denatured calf thymus DNA per ml, and a 32 P-labeled nick-translate d probe. Filters were washed a total of five times, finally in 0.1x SSPE-0.0033% Sarkosyl at 65oC. The probe was the 1.4-kb Sstl fragment of pAM97, isolated from agarose gels.
  • Genomic libraries and AM105 expression by E. coli - Initi al experiments investigated the specificity and sensitivity of immunoblot assays in detecting Anaplasma marginale proteins immobilized on nitrocellulose filters (26).
  • monoclonal and polyvalent antisera against Anaplasma marginale which has specificity for different surface proteins (17-19).
  • the reactions of these antisera with positive and negative control antigens are shown in Fig. 1A. All antibodies detected Anaplasma marginale erythrocytes and did not react with noninfected erythrocytes. The sensitivity of detection was greatest with R873, a rabbit antiserum against immunoaffinity-isolated Am105.
  • R873 detected as few as 1,200 parasitized erythrocytes in the 1 microliter spot applied to the filter. The specificity of each antibody in immunoblots was the same as that observed previously in immunoprecipitation experiments. Polyvalent or monoclonal antibodies against Am105 or another surface protein, Am36, reacted with the appropriate protein; there were not cross-reactions or reactions with the negative control, ovalbumin. R873 detected a minimum of 1 ng of purified AM105.
  • R781 was an antiserum prepared against isolated Anaplasma marginale initial bodies; it immunoprecipitated both Am105 (Am105U and Am105L) and Am36 (data not shown), and recognized Am105 and Am36 in immunoblots (Fig. 1A). We considered this assay sufficiently sensitive and specific to detect expression of Anaplasma marginale proteins in recombinant E. coli.
  • E. coli colonies containing recombinant plasmids of various sizes reacted stably with the antiserum (Fig. 1B).
  • All plasmids from expressing bacteria contained the inserted sequence present in pAM22; there were various lengths of additional insert DNA in the larger plasmids which expended beyond the Bglll sites.
  • R873 and R874 reacted with one or two normal E. coli proteins when used undiluted in immunoprecipitation, presumably because of prior exposure of rabbits to the bacterium.
  • the possibility of a cross-reaction between AM105 and E. coli proteins is considered less likely, because antisera to lysed nonrecombinant E. coli did not recognize Am105 (see Fig. 5 and 6).
  • the reaction of R873 with E. coli was not observed in immunoblot assays because the dilution of antiserum used 1:4,000) effectively removed anti-E. coli activity while retaining activity against Am105.
  • the molecular weight of the recombinant protein was identical in bacteria containing pAM25, pAM22, pAM97, or pAM113 plasmids.
  • the level of expression in each of these recombinants was also comparable, as judged by relative band intensity on SDS gels.
  • the orientation of insert DNA with respect to pBR322 had no apparent effect o n expression (both orientations were equally represented in the four plasmids.
  • Recombinant Am105 is structurally homologous to nonrecombinant Am105L. Recombinant Am105 was recognized by R873 and hence was antigenically homologous with Am105U and/or Am105L polypeptides. However, recombinant Am105, expressed by any of the recombinants, was not recognized by monoclonal antibodies 22B 1 or 15D 2 in immunoprecipitation or immunoblot assays (data not shown), or by R781 (Fig. 3, lanes 2 and 13). There were, therefore, important antigenic differences between recombinant and native Am105. We compared recombinant Am105 for structural homology with each component of the Am105 doublet, Am105L and Am105U.
  • Anaplasma marginale was radiolabeled with [ 35 S]methionine, solub ⁇ ized, and immunoprecipitated with the neutralizing monoclonal antibody 22B 1 , and the precipitated proteins were separated by electrophoresis in a 7.5% polyacrylamide-SDS gel containing 4 M urea (Fig. 4A, lane 3).
  • the Am105 doublet was clearly resolved. No bands were visible in the control lane ⁇ Anaplasma marginale plus 24A, monoclonal antibody, lane 4).
  • Recombinant Am105, immunoprecipitated by R873, was analyzed on the same gel. The recombinant Am105 migrated as a single band in an identrcal position to Am105L (Fig. 4A, lane 1).
  • the Am105 doublet in this gel system was resolved sufficiently to allow cutting out of the Am105L and Am105U components of the immunoprecipitate from a dried gel. Gel fragments containing each polypeptide were then rehydrated and analyzed by peptide mapping (5). Recombinant Am105, immunoprecipitated by R873, was also cut out and analyzed.
  • Figure 4B shows a peptide map obtained by partial digestion of the eluted polypeptides with S. aureus V8 protease.
  • Cleavage peptides of recombinant Am105 closely resembled those of Am105L.
  • Initial proteolysis products of both recombinant Am105 and AM105L were polypeptides of 75,000, 59,000, and 51,500 molecular weight.
  • Identical low-molecular-weight components 34,300, 18,600, and 13,000 to 16,000 were also generated. Therefore, the recombinant Am105 and AM105L molecules were homologous and possibly identical.
  • cleavage peptides produced from Am105U were largely dissimilar to both Am105L and recombinant Am 105.
  • Predominant digestion products of Am105U in the 22,000- to 27,000-molecular-weight range had no counterpart in Am105L or recombinant Am105.
  • Another peptide of 16,000 molecular weight was also absent from Am105L and recombinant Am105.
  • different peptides were generated from Am105L and AM105U by proteolysis, the sensitivity of this procedure did not permit a determination of total nonhomology between Am105L and Am105U.
  • cleavage peptides of 29,500 were produced from both Am105L and Am105U. Whether these two low-molecular-weight peptides share homology will require further structural analysis.
  • Antigenic relationships among recombinant Am105, Am105L, and Am105U polypeptides were investigated by preparing antisera against bacteria expressing recombinant Am105 in four rabbits; another four rabbits were immunized with E. coli containing pBR322 as a control. Sera were tested for recognition of nonrecombinant Am105 by an ELISA. All rabbits immunized with recombinant bacteria developed antibodies to Am105, ranging in titer from 1:100 to 1:1,000. No rabbits immunized with control E. coli developed antibodies to Am105. The anti-recombinant-Am105 sera immunoprecipitated both Am105L and Am105U from [ 35 S]methionine-labeled Anaplasma marginale (data not shown), and therefore reacted similarly to R873 and 22B 1 antibodies.
  • Am105L and Am105U may share antigenic determinants and therefore be immunoprecipitated together.
  • Am105L and Am105U may be antigenically unrelated but complexed. To discriminate between these possibilities, Am105L and Am105U were separately purified and immunoprecipitated. A detergent extract of [ 3S S]methionine-labeled Anaplasma marginale was first immunoprecipitated with monoclonal antibody 22B 1 , and the Am105L and Am105U components of the precipitate were separated by SDS gel electrophoresis.
  • Am105L and Am105U bands were cut out, electroeluted, and then separately immunoprecipitated again with monoclonal antibody 22B 1 or with rabbit anti-recombinant-Am105 serum (Fig. 5). Only Am105U was reimmunoprecipitated by 22B 1 ; Am105L was not recognized (lanes 4 and 5). In contrast, anti-recombinant-Am105 serum immunoprecipitated Am105L but not Am105U (lanes 8 and 9) when the two components were separated before immunoprecipitation. Therefore, recombinant Am105 was antigenically homologous only to Am105L.
  • Am105 exists as a complex of two polypeptides, Am105L and Am105U.
  • Monoclonal antibody 22B 1 recognizes an epitope present on Am105U, and binding to that epitope causes precipitation of both components of the complex.
  • the complex is stable in 1% Nonidet P-40 and 0.1% SDS, which are present in the immunoprecipitation reaction, but is dissociated by boiling in SDS gel sample buffer.
  • Am105L and Am105U are apparently not linked by disulfide bonds, because the molecular weight is unchanged when electrophoresis is performed under reducing or nonreducing conditions.
  • Recombinant Am105 is structurally and antigenically homologous to Am105L.
  • Anaplasma marginale genome contains multiple copies of the cloned Bglll fragment
  • Anaplasma marginale genomic DNA was cut with restriction enzymes; the DNA fragments were separated by gel electrophoresis, blotted to nitrocellulose, and probed with 32 P-labeled plasmid insert DNA from bacteria expressing recombinant Am105. By using enzymes which did not cut within the probe sequence, we observed multiple hybridizing bands (Fig. 7A, lanes 7 and 8).
  • the 4.0- and 6.7-kb bands must represent partially homologous copies of the 3.9-kb cloned Bglll fragment that do not have the HincIl or Mlul site or both. Similar digests with HincII plus Bglll or SstI, Bgll, or Bglll alone always produced the DNA fragment expected from the map in Fig. 2, but with between two and four additional hybridizing bands (Fig.7A and B). Multiple hybridizing bands were detected whether the HincII-Hindlll or SstI probes were used in detectio n (Fig. 7B, lanes 2 and 5). There was no hybridization between clone d probe and bovine leukocyte DNAs (Fig.
  • the cloned DNA faithfully represents an Anaplasma marginale genomic sequence.
  • additional partially homologous copies of the clones 3.9-kb Bglll fragment are also present in the genome.
  • Anaplasma marginale protein of approximately 105,000 molecular weight in recombinant E. coli.
  • the antisera prepared in rabbits against immunoaffinity-isolated, nonrecombinant Am105 recognize recombinant Am105 and vice versa, showing shared epitopes.
  • antisera against recombinant Am105 react with Anaplasma marginale in immunofluorescence and agglutinate purified initial bodies, demonstrating the presence of recombinant Am105 epitopes on the parasites themselves.
  • Recombinant Am105 is structurally and antigenically homologous to Am105L; no evidence was obtained for homology to Am105U.
  • Nonrecombinant Am105 containing both Am105L and Am105U, confers protection on cattle against challenge with Anaplasma marginale (17). It is not known whether Am105L or Am105U, used separated as an immunogen, would confer protection. Am105L and Am105U are both accessible on viable initial bodies to surface radiolabeling, one important criterion for an immunoprotective protein (1). Am105U may oe more likely to induce protection beca use this polypeptide contains the epitope recognized by neutralizing monoclonal antibody 22B ⁇ (Fig. 5). However, other neutralization-sensitive epitopes may also be present in Am105L, The epitope recognized in Am105U by antibody 22B, is conserved in eight geographically distinct isolates (17), an important practical concern for potential immunization.
  • Am105L gene copy was detected in recombinant libraries by expression screening. Other copies of the gene may not be complete and functional, similar to pilin genes of Neisseria gonorrhoeae (15, 16, 22). Alternatively, other Am105L genes may (i) contain promoter sequences that do not function in E. coli or Anaplasma marginale or (ii) code for antigenically variant forms of the protein not detected in the expression assay. An Am105L-related gene could code for Am105U, as peptide maps do not exclude the possibility of limited homology between Am105L and Am105U. However, later testing has indicated that the proteins Am105L and Am105U are the products of separate Anaplasma marginale genes as explained more fully below.
  • Anaplasma marginale may be a combination of surface proteins. These include Am86, Am61, Am36, and Am31 as well as Am105, Am105L or Am105U.
  • Anaplasma marginale gene was described here in structural and antigenic homology between the cloned and native surface proteins. Since cattle are protected against Anaplasma marginale by immunization with Am105 purified from infected erythrocytes (19), these results suggest that a recombinant vaccine is feasible and provide a rational basis for its development. PART IV - CLONING OF MSP-1 GENES FOR DIFFERENT
  • the antigens may hereinafter be referred to by the "Am” designation as used above, with an additional abbreviation such as "F” for Florida, to designate the geographical isolate.
  • Am105 generally referred to above in this application is also referred to as AmF105 to indicate the association with the Florida isolate.
  • a portion of the MSP-1a gene for the Florida isolate which codes for a subunit of AmF105U was obtained in a 2.7 kilobase pair (kbp) insert cloned into the plasmid pUC9 to produce a plasmid herein termed pAMT1.
  • plasmid pAMT1 When plasmid pAMT1 was inserted into E. coli it caused the synthesis of an antigen containing a subunit of AmF105U having an approximately 56,000 dalton molecular weight.
  • the portion of the AmF105U antigen expressed by this recombinant bacterial cell is indicated in the amino acid sequence information given in Fig. 12 for the Florida isolate starting with amino acid 1 through approximately 220-230 in repeat 8.
  • coli strain DH5a The bacterial transformants were screened by colony hybridization according to the procedures of Grunstein and Hogness, Proceedings of National Academy of Sciences. (U.S.A.) 72. 3961 (1975). The procedure was accomplished using a 1 Kbp DNA fragment of plasmid pAMT1 radiolabeled with 32 P as a hybridization probe, which was extracted from the Kpnl site (see corresponding point on Florida isolate restriction map) to the right end of plasmid pAMT1 as shown in Fig. 8.
  • the blocked-in or bolded linear regions of the plasmid diagrams shown in Fig. 8 correspond to the regions of the four geographical isolates of An ⁇ pl ⁇ sma marginale which were DNA sequenced (see Fig.
  • Fig. 8 10 for DNA sequences.
  • the polypeptides were fractionated on 7.5-17.5% gradient polyacrylamide gels, and transferred electrophoretically to nitrocellulose, and probed with monoclonal antibody 22B1 and 125 I-protein A.
  • the bands containing the products of the MSP-1a gene recognized by monoclonal antibody 22B1 are indicated by arrowheads.
  • Molecular weight standards shown at the right of that Fig. are given in kilodaltons.
  • Lanes 1,3,5, and 7 are recombinants pVA1, pWAO1, pID6 and pFL10, respectively.
  • Lanes 2, 4, 6, and 8 are polypeptides produced by VA, WA, ID and FL Anaplasma marginale initial bodies.
  • DNA sequences for the four different geographical isolates of Anaplasma marginale were obtained as shown in Fig. 10.
  • the DNA inserts in the recombinant plasmids pGEM4 were sequenced using the dideoxynucleotide method of Sanger et al., Proceedings of National Academy of Sciences (U.S.A.) 82, 648 (1985).
  • the SP6 and t7 promoter primers of pGEM4 were used to prime the initial sequencin g reactions. Once into each insert, new primers were synthesized based on the sequences just obtained and used to extend the regio n sequenced.
  • sequences are given from the 5' Kpnl site of each clone to the same point representing the 3' end of the Florida isolate cloned insert
  • Annotations above the sequences indicate the Kpnl site, features of the promoter region, the start of transcription, the start and stop codons of the coding sequence, and the repeat units. Variant bases are indicated by asterisks beneath the sequence, whereas insertion or deletions are indicated by dashes. A region of homology near th e 3' end which is contained in repeat regions is double underlined there and in the repeat regions. Further discussion of notable points about the DNA sequences will be given below.
  • indicated antigens such as Am220, Am105 (complex), Am105U, Am105L, Am86, Am61, Am56, Am42, Am36, Am31 and Am25; even more preferably Am105 (complex), Am105U, Am105L, Am86, Am61, Am36, Am31, and Am15; from the Florida isolate as used in the research indicated above, or the antigenically similar proteins and polypeptides from other isolates of Anaplasma marginale might be produced by such recombinant techniques.
  • such recombinant techniques may be applied to determine the DNA and/or polypeptide sequences of the desired antigenic, and in applicable uses immunogenic, proteins or polypeptides.
  • the amino acid sequence information can then be used to produce the antigenic polypeptides according to well-known polypeptide synthesis techniques which are commercially available given knowledge of the desired polypeptide sequence to be constructed.
  • the antigens, vaccines, recombinant vectors and recombinant cells, methods and other aspects of this invention are in there broader concepts applicable to the broader classes of Rickettsiae since at least one member thereof is immunologically treatable and detectible using the antigens and vaccines of this invention. This in particular applies to the more specific nucleic acid and amino acid sequences, described above and in more detail below, which are known effective for inducing an immune response against such parasitic organisms.
  • Portions of each of the four DNA inserts of the recombinant plasmids pFL10, pID6, pWAO1, pVA1, and plasmid pAMT1 were sequenced with the sequenced portions of the four isolate derived plasmids indicated by the bold lining in Fig. 8 and by the DNA sequences shown in Fig. 10, except pAMT1 which is not shown in Fig. 10 because it is redundant with portions shown for pFL10.
  • RNA from the Florida isolate Anaplasma marginale initial bodies was sequenced using a primer specific to a region near the 5' end of the only significant open reading frame (ORF), according to a procedure indicated by Vander Ploeg et al., Nucleic Acids Research 10, 3591 (1982).
  • ORF open reading frame
  • the RNA was sequenced directly with Avian Myeloblastosis Virus reverse transcriptase by a modification explained in Hollingshead et al, Molecular Cell Genetiics 207, 196 (1987), of the method of Inoue and Cech, National Academy of Sciences (U.S.A.) 82, 648 (1985).
  • the FL, VA and WA alleles are identical from the transcription start site to the 5' end of the -35 region.
  • the ID allele has a 1 base deletion within the -35 region, at position -30FL.
  • the spacing between the -35 and -10 regions is maintained, however, by insertion of a T at position -22FL (see Figs. 10 and 11B) and all four alleles match that of the E. coli consensus sequence.
  • Immediately 5' to the -35 region is an extremely A+T-rich stretch in which A or T occupy 23 of the 25 bases in that sequence.
  • the VA and WA alleles are identical in this region except for an A to G transition at position 10FL.
  • the ID allele has a T to G transversion at position 8FL and deletions of 1, 51 and 4 bases in this region.
  • the FL, WA and ID alleles are expressed at comparable levels in E. coli (DH5a).
  • VA is not comparably expressed, this may be because of differences in plasmid copy number or products encoded by sequences 3' to the end of the MSP-1a gene which are absent from the other recombinants. We have not pursued this question.
  • the first 30 bases of the DNA coding sequence comprises a hypervariable region wherein FL, VA and WA each have 4 substitutions, whereas ID has only 27 bases in the same region, of which 7 vary from the other isolates.
  • the result is an associated N-terminal amino acid region shortened from 10 to 9 amino acids, with 4 substitutions between isolates, three of which are non-conservative.
  • a similar clustering of substitutions at the 3' end results in 5 amino acid differences in the final 35 residues.
  • the 120 bp stretch from bases 1184FL to 1202FL is a highly variable region, with 11 base substitutions resulting in the substitution of 11 out of 40 amino acids (see Figs. 10 and 12). Eight of these substitutions are non-conservative, and 7 of the 11 are in regions predicted to be short coil-turn structures. This may be important to host responses to this antigen.
  • a notable feature of the MSP-1a gene for all four isolates is the presence of a DNA tandem repeat region containing a series of similar tandemly repeated DNA sequences which each contain 84 or 87 bp. These DNA tandem repeat sequences code for the expression of polypeptide sequences having 28 or 29 amino acids, respectively.
  • tandemly repeated sequences are repeated two times in the VA isolate, four times in the WA isolate, six times in the ID isolate, and eight times in the FL isolate. It is interesting that each of the alleles varies by a multiplicative factor of two in the number of repeats but we cannot at this time ascribe any particular significance to this observation.
  • the tandem repeats of 28 or 29 amino acid units immediately follow the N-terminal 10 (or 9) amino acids.
  • Fig. 13 shows that the repeated amino acid sequences are present in only five forms, herein termed repeat forms A-E, for all repeat sequences contained in the tandem repeat regions of the four Anaplasma marginale isolates.
  • Each geographical isolate allele contains two repeat forms.
  • the primary structures of the various repeat forms are highly conserved with 25 amino acids of the 28 or 29 mer sequences being completely conserved in all five repeat forms defining all tandemly repeated sequences of these isolates.
  • the tandem repeat domain begins or ends with a single copy of one repeat form whereas the second repeat form is present in one to seven copies. Variation s in the number of tandem repeats present in each allele can completely explain the size polymorphisms of the Am105U protein for these four geographical isolates of Anaplasma marginale without any need to invoke other mechanisms to explain the differences.
  • the 28 and 29 mer amino acid sequences shown in Fig. 13 include conserved amino acid sequences DSSSA, GQQQESSVSSQS, EASTSS or QASTSS, and QLG. One or more of these sequences or their subunits can be significant in defining antigens in accordance with this invention.
  • Antibody 22B1 selectively binds to sequences EASTSS and QASTSS as explained more fully below. Antibody titers have been developed in cattle against the Florida isolate 29 mer polypeptide shown in Fig. 13 as repeat form B.
  • Coupling of one or more of these repeat sequences to additional polypeptide sequences may also be significant in stimulating an immune response which is characterized by the 28 or 29 mer amino acids sequences, or subunits thereof, such as the conserved subunits indicated in this document.
  • These highly conserved tandem repeat units or homologous regions may also be conserved in other rickettsial organisms, thereby allowing additional rickettsial infections to be detected, treated or vaccinated against using the antigens and immunogens including these amino acid sequences, there subunits or combinations thereof.
  • bases -1188FL to -1208FL which include the DNA sequence TTAtGcGCaGATgcCaCcTCA. This region shares 14 of 21 bases.
  • the third homologous region, bases -1292FL to -1308FL (also not shown) (TCAGOGGGTcGTCAGCA), shares 16 of 17.
  • the fourth homologous region, bases -1450FL to -1461FL (CgGCAGgAAGcG), shares 9 of 12 bases.
  • the four homologous regions overlap an area of the repeat sequence exemplified by bases 260FL-274FL, 236FL- 256FL- 254-270FL and 266FL-277FL, respectively.
  • the fifth homologous region bases -496FL to -516FL (CAGGaCcGcAaATGgGcCTCAA), shares 15 of 21 bases with a stretch exemplified by bases 302FL to 322FL. These homologous regions may reflect the origin of the repeats as discussed below.
  • Plasmid pAMT1 encodes a subunit polypeptide of AmF105U which is recognized by monoclonal antibody 22B1 yet contains only the N-termina. 10 amino acid stretch and seven complete and one partial repeats. Because of this we targeted our search to the repeat structure. Our approach was to assay the binding ability of monoclonal 22B1 to various synthetic oligopeptides containing overlapping stretches of the B repeat.
  • Oligopeptides of varying lengths and containing different regions of the A and B repeats of the antigen AmF105U polypeptide were assayed for monoclonal antibody 22B1 binding affinity.
  • a (+) reaction indicates monoclonal 22B1 binding in these assays.
  • An (-) reaction indicates no detectable monoclonal 22B1 binding.
  • Results were obtained by solution- phase inhibition radioimmunoassay using 125 I-labeled AmF105, which were confirmed by an enzyme-linked immunosorbent assay and by immunoblot assays. The enzyme-linked assay was performed as described previously by Palmer et al., International Journal for Parasitology, 17, 1279 (1987), with the following modifications.
  • microtiter plates were first coated with bovine serum albumin to which was added the oligopeptides in 0.25% (w/v) glutaraldehyde, 10 mM sodium phosphate, 94 mM ethylenediamine tetraacetic acid, pH 6.8. Blocking and washing steps were done using a veronal buffer of the following composition: 145 mM sodium chloride, 1.8 mM sodium 5,5'- diethylbarbiturate, 4.5 mM barbituric acid, 0.5mM MgCl 2 .
  • the visualizing system was horseradish peroxidase coupled to recombinant Protein G.
  • Synthetic 29 mer oligopeptides containing the sequence shown in Fig. 13 as Form B were tested in calves to determine the antigenic capability of this sequence. Two calves were given 400 microgram doses at four times. The first injection was given in approximately 1-2 milliliters of Freund's complete adjuvant Three boosters containing similar amounts of the antigenic oligopeptide were given thereafter at approximately 2 week intervals. Three additional calves were similarly inoculated with another vaccine incorporating similar amounts of an antigen containing the synthetic 29 mer oligopeptides which had been polymerized with the cross-linking agent carbodiimide to produce antigens having approximate electrophoretic mobilities corresponding to molecular weights of 20,000 to 200,000 daltons, Science 144, 1344 (1964).
  • the entire repeat domain is predicted by structural algorithms to be comprised of coil/turn segments, consistent with a short, linear epitope.
  • the binding affinity of monoclonal 22B1 for the entire 29 mer repeat B was approximately two orders of magnitude greater than for either minimal epitope, suggesting some structural influence.
  • variable numbers of repeats there are three highly variable regions in the polypeptide, including the N-terminal end.
  • the gene uses promoter structures and spacings very similar t o the E. coli promoter consensus sequences. Despite the similarities between the MSP-1a promoter and E. coli promoter consensus sequences, one significant difference emerged: No obvious ribosome binding site was detected in the untranslated leader region, even though this gene is expressed in E coli in appreciable amounts.
  • the sequence GTGTGTG found in the -11 to -5 (relative to the ATG codon) position may still base pair with the ribosomal RNA but with a lowered affinity.
  • AmF105 polypeptide An unusual structural feature of the AmF105 polypeptide is that although it is a surface protein and accessible to antibody, no obvious signal sequence to promote its translocation to the outer membrane bilayer was detected.
  • a hydropathy plot of the predicted polypeptide reveals five major hydrophobic stretches from amino acids 255FL-270FL, 541FL-557FL, 567FL-585FL, 631FL-650FL, and 662FL-678FL, the last four of which are sufficient in length and hydrophobicity to serve as transmembrane domains.
  • One of these hydrophobic domains may serve as an uncleaved, internal signal sequence.
  • tandem repeat structures have been hypothesized to develop by multiple events of unequal homologous recombination and/or slipped- strand mispairing.
  • the origin of the tandem repeats in AmF105 is unknown. Sequences sharing significant homology with the repeats are also seen at other sites within and outside the MSP-1a gene coding sequence. Given the lengths of the tandem repeats (84 or 87 bp), unequal homologous recombination is the more likely mechanism as longer sequences reduce the probability of slipped-strand mispairing.
  • MSP-1a gene has clarified one molecular basis for rickettsial surface antigen size polymorphisms. Having defined several features of the MSP-1a gene will enable us to map T-cell epitopes of AmF105 and to assess the potential for T-cell epitope-based antigen variation in Anaplasma marginale. The applicability to other rickettsial organisms can also be further investigated. Definition of a conserved neutralization-sensitive epitope allows us to further assess the immunoprotective of synthetic, including recombinantly produced, peptide-based vaccines.
  • Fig. 15 is a restriction enzyme map for the MSP-1b Florida gene showing the cutting sites for a variety of enzymes.
  • Fig. 16 shows the DNA and associated amino acid sequences coded for by the AmF105L gene. The last part of Fig.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Des protéines de surface antigéniques purifiées d'Anaplasma marginale ont été identifiées et peuvent induire des réponses d'immunisation chez les ruminants pour neutraliser l'Anaplasma marginale virulente. Les protéines de surface antigéniques ont un ou plusieurs composants présentant des mobilités électrophorétiques correspondant à un poids moléculaire d'environ 15.000 daltons, 86.000 daltons, 61.000 daltons, 36.000 daltons, 31.000 daltons ou 15.000 daltons, et peuvent être purifiées par un procédé de chromatographie à immuno-affinité comprenant les étapes de rupture des corps initiaux d'Anaplasma marginale par traitement avec un détergent, de passage des corps initiaux rompus sur une colonne de chromatographie comprenant une matrice insoluble couplée à des anticorps monoclonaux contre un déterminant sur ladite protéine de surface antigénique pour lier sélectivement ladite protéine de surface antigénique auxdits anticorps monoclonaux, et de récupération de la protéine de surface antigénique sensiblement pure de la matrice insoluble. Les antigènes sont en outre utiles dans les tests pour diagnostiquer une anaplasmose. Ils peuvent être synthétisés par des procédés polypeptidiques ou par génie génétique. Des séquences d'acides aminés et d'ADN ont été développées pour au moins certains des antigènes de cette invention. Les antigènes peuvent être utiles pour des organismes de la bactérie Rickettsia autres que l'Anaplasma marginale.
PCT/US1990/001678 1989-04-06 1990-03-30 Antigenes de la bacterie de rickettsia pour la vaccination et le diagnostic WO1990012030A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU55214/90A AU644362B2 (en) 1989-04-06 1990-03-30 Rickettsial antigens for vaccination and diagnosis
CA002049986A CA2049986A1 (fr) 1989-04-06 1990-03-30 Antigenes de ricketties a des fins de vaccination et de diagnostique

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33517889A 1989-04-06 1989-04-06
US335,178 1989-04-06

Publications (1)

Publication Number Publication Date
WO1990012030A1 true WO1990012030A1 (fr) 1990-10-18

Family

ID=23310630

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1990/001678 WO1990012030A1 (fr) 1989-04-06 1990-03-30 Antigenes de la bacterie de rickettsia pour la vaccination et le diagnostic

Country Status (4)

Country Link
EP (1) EP0467972A4 (fr)
JP (1) JPH04504422A (fr)
CA (1) CA2049986A1 (fr)
WO (1) WO1990012030A1 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0444441A2 (fr) * 1990-03-01 1991-09-04 Hewlett-Packard Company Minimisation de la largeur des bandes d'éluats en chromatographie en phase liquide
WO1998016554A1 (fr) * 1996-10-17 1998-04-23 University Of Florida Vaccins a base d'acide nucleique contre les rickettsioses et methodes d'utilisation
US5869335A (en) * 1995-08-25 1999-02-09 Regents Of The University Of Minnesota Method of growing rickettsiae in Ixodes scapularis tick cell culture and preparing antigens and vaccines of rickettsiae
US6593147B1 (en) 1996-10-17 2003-07-15 University Of Florida Research Foundation, Inc. Nucleic acid vaccines against rickettsial diseases and methods of use
US6653128B2 (en) 1996-10-17 2003-11-25 University Of Florida Nucleic acid vaccines against rickettsial diseases and methods of use
US7138247B2 (en) 1999-12-07 2006-11-21 Stressgen Biotechnologies Corporation Compositions and methods for detecting stress-inducible proteins
US7501234B2 (en) 1989-06-15 2009-03-10 Whitehead Institute For Biomedical Research Stress proteins and uses therefor
US7501125B2 (en) 2000-01-14 2009-03-10 Whitehead Institute For Biomedical Research Vivo CTL elicitation by heat shock protein fusion proteins maps to a discrete domain and is CD4+ T cell-independent
US10227665B2 (en) 2012-01-26 2019-03-12 Luc Montagnier Detection of DNA sequences as risk factors for HIV infection

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6311959B2 (ja) * 2012-10-04 2018-04-18 国立大学法人三重大学 微生物の迅速診断を可能とする特異抗体の高効率作製法

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACT, Volume 108, No. 3, issued 18 January 1988. PALMER et al. "Characterization of neutralization-sensitveeptope on the am 105 surface protein of Anaplasma morginale", Abstract 20189v, 1987, Int. J. Parasitol. 17(7), 1279-85 (Eng). *
CHEMICAL ABSTRACTS, Volume 107, No. 4, issued 27 July 1987. BARBET et al. "Anaplasma marginale subunit antigen for vaccination and tiagnosis", Abstract 28359a, 01 October 1986, Eur. Pat. Appl. EP 196,290. *
Dissertation Abstracts, Volume 47/08-B, 1986, ADAMS "Identification and Partial characterization of the antigens of Anaplasma marginale (Florida) and Anaplasma caudatum (Illinois) Ph.D, dissertation University of Illinois at Urbana-Champaign. *
Infection and Immunity "Characterization of an immunroprotective protein complex of Anaplasma marginale by cloning and expression of the gene coding for polypeptide Am IOSL" Volume 55, No. 10, p. 2428-2435. BARBET et al. October 1987. See Abstract. *
Infection and Immunity "Immunization of Cattle with the MSP-1 surface protein complex induces protection against structurally variant Anaplasma marginale isolate" Volume 57, No. 11, page 3669. PALMER et al November 1989. See Abstract. *
Infection and Immunity "Molecular size variations in an immunoprotectiv3 protein complex among isolates of Anaplasma marginale" Volume 56, No 6, page 1567- 1573. OBERLE et al. June 1988. See Abstract. *
See also references of EP0467972A4 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7501234B2 (en) 1989-06-15 2009-03-10 Whitehead Institute For Biomedical Research Stress proteins and uses therefor
EP0444441A2 (fr) * 1990-03-01 1991-09-04 Hewlett-Packard Company Minimisation de la largeur des bandes d'éluats en chromatographie en phase liquide
EP0444441A3 (en) * 1990-03-01 1992-09-09 Hewlett-Packard Company Minimizing eluate band widths in liquid chromatography
US5869335A (en) * 1995-08-25 1999-02-09 Regents Of The University Of Minnesota Method of growing rickettsiae in Ixodes scapularis tick cell culture and preparing antigens and vaccines of rickettsiae
US6593147B1 (en) 1996-10-17 2003-07-15 University Of Florida Research Foundation, Inc. Nucleic acid vaccines against rickettsial diseases and methods of use
US6251872B1 (en) 1996-10-17 2001-06-26 University Of Florida Nucleic acid vaccines for ehrlichia chaffeensis and methods of use
US6025338A (en) * 1996-10-17 2000-02-15 University Of Florida Nucleic acid vaccines against rickettsial diseases and methods of use
US6653128B2 (en) 1996-10-17 2003-11-25 University Of Florida Nucleic acid vaccines against rickettsial diseases and methods of use
WO1998016554A1 (fr) * 1996-10-17 1998-04-23 University Of Florida Vaccins a base d'acide nucleique contre les rickettsioses et methodes d'utilisation
US7138247B2 (en) 1999-12-07 2006-11-21 Stressgen Biotechnologies Corporation Compositions and methods for detecting stress-inducible proteins
US7326574B2 (en) 1999-12-07 2008-02-05 Stressgen Biotechnologies Corporation Compositions and methods for detecting stress-inducible proteins
US7501125B2 (en) 2000-01-14 2009-03-10 Whitehead Institute For Biomedical Research Vivo CTL elicitation by heat shock protein fusion proteins maps to a discrete domain and is CD4+ T cell-independent
US10227665B2 (en) 2012-01-26 2019-03-12 Luc Montagnier Detection of DNA sequences as risk factors for HIV infection

Also Published As

Publication number Publication date
EP0467972A4 (en) 1992-09-02
JPH04504422A (ja) 1992-08-06
EP0467972A1 (fr) 1992-01-29
CA2049986A1 (fr) 1990-10-07

Similar Documents

Publication Publication Date Title
Fikrig et al. Roles of OspA, OspB, and flagellin in protective immunity to Lyme borreliosis in laboratory mice
Wallich et al. Molecular cloning and immunological characterization of a novel linear-plasmid-encoded gene, pG, of Borrelia burgdorferi expressed only in vivo
Howe et al. Acute virulence in mice is associated with markers on chromosome VIII in Toxoplasma gondii
Goldbaum et al. Characterization of an 18-kilodalton Brucella cytoplasmic protein which appears to be a serological marker of active infection of both human and bovine brucellosis
EP0650527B1 (fr) Amelioration dans le diagnostic et la prophylaxie de la borreliose provoquee par borrelia burgdorferi
Akins et al. A new animal model for studying Lyme disease spirochetes in a mammalian host-adapted state.
US6183986B1 (en) OspA DNA and lyme disease vaccine
Kim et al. High-level expression of a 56-kilodalton protein gene (bor56) of Rickettsia tsutsugamushi Boryong and its application to enzyme-linked immunosorbent assays
Vidotto et al. Intermolecular relationships of major surface proteins of Anaplasma marginale
AU592389B2 (en) Antigenic proteins and vaccines containing them for prevention of coccidiosis
CA1340520C (fr) Proteines antigeniques et vaccins qui en renferment; anticorps protecteurs diriges vers eux pour prevenir la coccidiose causee par eimera tenella et eimera necatrix
EP0536335A1 (fr) Compositions et procedes pour la prevention et le diagnostic de la maladie de lyme
SK217292A3 (en) Vaccine containing a pc protein useful in prevention of lyme disease, method of b.burgdorferi protein purification, diagnostic agent detecting b.burgdorferi antigens and method of detecting b.burgdorferi antigenes in humoralis
Lightowlers et al. Immunization against Taenia taeniaeformis in mice: studies on the characterization of antigens from oncospheres
US5777095A (en) Osp A and B Sequence of Borrelia burgdonferi strains ACA1 and IP90
CA2077434C (fr) Proteines antigeniques de borrelia burgdorferi
Gilmore Jr et al. Conformational nature of the Borrelia burgdorferi B31 outer surface protein C protective epitope
Wright et al. Protection of Babesia bigemina-immune animals against subsequent challenge with virulent Babesia bovis
WO1990012030A1 (fr) Antigenes de la bacterie de rickettsia pour la vaccination et le diagnostic
WO2002016422A2 (fr) Constructions recombinantes de borrelia burgdorferi
WO1997045540A1 (fr) GENES DE PROTEINE DE EHRLICHIA CHAFFEENSIS IMMUNODOMINANTS DE 120 kDa PAR ADHESION EN SURFACE
US5549898A (en) Immunogenic anaplasma marginale surface antigens, compositions, and methods of use
Wright et al. Protective vaccination against virulent Babesia bovis with a low-molecular-weight antigen
WO1990011776A1 (fr) Proteines et genes clones nouveaux utiles pour le diagnostic et la prophylaxie de la babesiose
US5470712A (en) Antigenic proteins of Borrelia burgdorferi

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA DK JP KR

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB IT LU NL SE

WR Later publication of a revised version of an international search report
WWE Wipo information: entry into national phase

Ref document number: 1990906659

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2049986

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 1990906659

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1990906659

Country of ref document: EP

ENP Entry into the national phase

Ref country code: CA

Ref document number: 2049986

Kind code of ref document: A

Format of ref document f/p: F